Skip to content
  • Home
  • World News
  • Business
  • Aviation
195 news

195News

All the news that's fit to print

  • Home
  • World News
  • Business
  • Aviation
  • Toggle search form
  • Minerals Security Partnership Governments Engage with African Countries and Issue a Statement on Principles for Environmental, Social, and Governance Standards
    Minerals Security Partnership Governments Engage with African Countries and Issue a Statement on Principles for Environmental, Social, and Governance Standards World News
  • ‘Ensure Everyone We Touch Has a Better Life’: Omaha Company Prioritizes Giving in 2022
    ‘Ensure Everyone We Touch Has a Better Life’: Omaha Company Prioritizes Giving in 2022 Business
  • Key Drivers of the Ride Hailing Market in 2024: On-Demand Transportation Services
    Key Drivers of the Ride Hailing Market in 2024: On-Demand Transportation Services World News
  • OTC) Welcomes a Transformative Landscape for the Crypto Market
    OTC) Welcomes a Transformative Landscape for the Crypto Market Business
  • War Day 133: war diaries w/Advisor to Ukraine President, Intel Officer @arestovych  & #Feygin
    War Day 133: war diaries w/Advisor to Ukraine President, Intel Officer @arestovych & #Feygin World News
  • Wencor Announces Global Distribution Partnership With TA Aerospace
    Wencor Announces Global Distribution Partnership With TA Aerospace World News
  • Hallite to Present New and Innovative Hydraulic Sealing Solutions at China Coal & Mining Expo 2023 in Beijing
    Hallite to Present New and Innovative Hydraulic Sealing Solutions at China Coal & Mining Expo 2023 in Beijing Business
  • War Day 134: war diaries w/Advisor to Ukraine President, Intel Officer @arestovych  & #Feygin
    War Day 134: war diaries w/Advisor to Ukraine President, Intel Officer @arestovych & #Feygin World News
Gb Sciences’ Plant-based Formulations Designed to Treat Anxiety Achieve Statistical Significance in Animal Study

Gb Sciences’ Plant-based Formulations Designed to Treat Anxiety Achieve Statistical Significance in Animal Study

Posted on October 24, 2022 By NewsEditor
Gb Sciences’ Plant-based Formulations Designed to Treat Anxiety Achieve Statistical Significance in Animal StudyGb Sciences’ Plant-based Formulations Designed to Treat Anxiety Achieve Statistical Significance in Animal StudyGb Sciences' anxiety formulations were previously identified using the company's AI-driven PhAROS™ platform, and they have now been evaluated using preclinical zebrafish models of stress at the National Research Council of Canada.

Gb Sciences’ Plant-based Formulations Designed to Treat Anxiety Achieve Statistical Significance in Animal Study
GB Sciences


LAS VEGAS - October 24, 2022 - (Newswire.com)

Gb Sciences, Inc. ("GbS"; OTCQB:GBLX), a leading plant-inspired research and biopharmaceutical drug development company, has received positive preclinical results in an interim report from its study using preclinical zebrafish models of stress at the National Research Council of Canada (NRC). GbS' proprietary anxiety formulations have achieved a statistically significant reduction of stress in this preclinical study. The NRC is testing GbS' proprietary, psychotropic plant-based formulas for the treatment of depression and anxiety. GbS has leveraged its patent-pending PhAROS™ (Phytomedical Analytics for Research Optimization at Scale) platform to identify these combinations of plant compounds for novel drug candidates. These are the company's first non-cannabis formulations to advance in preclinical studies.

"We have achieved an important milestone in the development of our novel, kava-inspired anxiety formulations. Not only did some of our formulations achieve statistical significance in the animal model, but these minimum essential mixtures also demonstrated synergy by significantly outperforming the individual active ingredients within our minimum essential mixture formulations," said Dr. Andrea Small-Howard, Gb Sciences' President and Chief Science Officer. "This preclinical data also confirms that our PhAROS™ platform was capable of yielding concrete, potentially effective, plant-inspired combination drugs."

For these novel psychotropic drug candidates, the Gb Sciences research team used the PhAROS™ platform to identify new ingredients to improve upon an initial formulation for anxiety based on traditional medicine. The original plant mixture was derived from the kava plant, but some elements of kava are thought to cause liver toxicity. PhAROS™ identified ingredients from the Piper plant family as a substitute for the functionality of the ingredients in question without the potentially adverse safety profiles of those original ingredients. The Piper plant family includes pepper plants that are used worldwide in traditional medicines.

The PhAROSTM platform is a revolutionary, AI-driven science gateway and virtual research environment for drug discovery. With its data analytics and machine learning capabilities, PhAROS™ allows Gb Sciences to greatly reduce the time and money required to bring novel, plant-inspired formulations to market. PhAROS™ represents a breakthrough combination of data sciences and traditional plant-based medicines. 

To learn more about Gb Sciences, visit www.gbsciences.com.

About Gb Sciences and GbS Global Biopharma

Gb Sciences, Inc. is a plant-inspired, biopharmaceutical research and development company creating patented, disease-targeted formulations of cannabis- and other plant-inspired therapeutic mixtures for the prescription drug market through its Canadian subsidiary, GbS Global Biopharma, Inc. The 'plant-inspired' active ingredients in its therapeutic mixtures are synthetic homologues identical to the original plant compounds but produced under current Good Manufacturing Practices. Gb Sciences' intellectual property portfolio contains six issued U.S. and three issued foreign patents, as well as 17 U.S. and 51 foreign patent-pending applications. In its drug development pipeline, Gb Sciences has five preclinical phase product development programs. Gb Sciences' lead program for Parkinson's disease is being prepared for a first-in-human clinical trial. Gb Sciences' formulations for chronic pain, anxiety, and depression are currently in preclinical animal studies with researchers at the National Research Council of Canada (NRC). The company also received positive preclinical proof-of-concept data supporting its complex mixtures for the treatment of Cytokine Release Syndrome, and its lead candidates will be optimized based on late-stage preclinical studies at Michigan State University. Gb Sciences' productive research and development network includes distinguished universities, hospitals, and Contract Research Organizations. To learn more, visit www.gbsciences.com. 

Forward-Looking Statements

This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as "expects," "intends," "plans," "may," "could," "should," "anticipates," "likely," "believes" and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control. It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

Media Contact

Alexis Quintal

[email protected]


Contact Information:
Madeleine Moench
[email protected]


Press Release Service by Newswire.com

Original Source: Gb Sciences' Plant-based Formulations Designed to Treat Anxiety Achieve Statistical Significance in Animal Study
Business

Post navigation

Previous Post: Genomes Partners With CariGenetics to Launch a Decentralized Lab for Breast Cancer Research
Next Post: NREP Launched New Emergency Planning Professional Certification

Related Posts

  • Dolman Law Group Currently Accepting Hair Relaxer-Uterine Cancer Cases
    Dolman Law Group Currently Accepting Hair Relaxer-Uterine Cancer Cases Business
  • Stay in a Historic Palazzo Where Culture Meets Connectivity at Butera 28 Apartments
    Stay in a Historic Palazzo Where Culture Meets Connectivity at Butera 28 Apartments Business
  • Edison Aerospace to Present at NAAA convention
    Edison Aerospace to Present at NAAA convention Business
  • Southwestern Scale Announces Expansion Into Colorado
    Southwestern Scale Announces Expansion Into Colorado Business
  • Tru Treasury and ZSuite Tech Announce Strategic Collaboration, Launching Innovative Escrow Tool for Credit Unions
    Tru Treasury and ZSuite Tech Announce Strategic Collaboration, Launching Innovative Escrow Tool for Credit Unions Business
  • PenFactory to Celebrate International Women’s Day With 15% Off Sitewide
    PenFactory to Celebrate International Women’s Day With 15% Off Sitewide Business
August 2025
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
« Jul    
last celebrity gossip
Gossip Stone - celebrity life and gossip

Recent Posts

  • Weather Risks Shouldn’t Deter Vacation TravelAugust 24, 2025
  • Aerospace & Defense Materials Market Size $81.1 billion By 2031: Industry Growth, Drivers & Future ScopeAugust 23, 2025
  • Ecuadorian Immigrant Trains Over 100 New Insurance Agents in First Year in the U.S.August 23, 2025
  • Mary Ann Scully at Loyola University Maryland Recently Featured on Close Up RadioAugust 23, 2025
  • Project Boon Delivers Backpacks, Groceries, and Resources to Riverside Families in Back-to-School CelebrationAugust 21, 2025
Brand Values Content
VUGA Enterprises - media network PR & Marketing
  • VLink Inc. Accelerates Global Expansion with New Offices in India and Canada
    VLink Inc. Accelerates Global Expansion with New Offices in India and Canada World News
  • Key Drivers of the Ride Hailing Market in 2024: On-Demand Transportation Services
    Global Smoke Detectors Market 2024 To Reach $2.49 Billion By 2028 With A Growth Rate Of 5.5% World News
  • Day 371: war diaries w/Former Advisor to Ukraine President, Intel Officer @arestovych & #Feygin
    Day 371: war diaries w/Former Advisor to Ukraine President, Intel Officer @arestovych & #Feygin World News
  • War Day 29 :: conversations with @Alexey Arestovych
    War Day 29 :: conversations with @Alexey Arestovych World News
  • International Women’s Day, Gala Dinner by PCHS “Celebrating the Resilience”
    International Women’s Day, Gala Dinner by PCHS “Celebrating the Resilience” World News
  • Minerals Security Partnership Governments Engage with African Countries and Issue a Statement on Principles for Environmental, Social, and Governance Standards
    Assistant Secretary Witkowsky’s Travel to Belgium and the United Kingdom World News
  • Popular Politics – 365 Days of War in 5 Minutes, original audio with  English Subtitles
    Popular Politics – 365 Days of War in 5 Minutes, original audio with English Subtitles World News
  • North America Medical Laser Systems Market Reach US$ 2,257.13 million by 2028 at 13.7% CAGR
    North America Medical Laser Systems Market Reach US$ 2,257.13 million by 2028 at 13.7% CAGR World News
aerospace company
stem cell clinic in kiev
medical spa in miami
Fashion TV free

Copyright © 2023 195 News. All Rights Reserved by Coolaser | Partner of VUGA Enterprises |  Advertising: Get Published

Powered by .